Houston Methodist scientists have uncovered an unexpected side of a protein best known for its link to brain diseases. The ...
The FDA approved the Dako Omnis panel to identify patients with colorectal cancer with mismatch repair deficiency. The mismatch repair immunohistochemical panel pharmDx (Dako Omnis) has received U.S.
The Dako Omnis test identifies mismatch repair deficiencies in colorectal cancer, aiding in treatment decisions and potentially improving patient outcomes. Hernexeos, a kinase inhibitor, offers a new ...
I. Platinum-based therapies induce DNA inter-strand crosslinks (ICLs), which exacerbate genomic instability and impede DNA replication. In BRCA1/2-deficient tumor cells, the repair of these DNA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results